Cargando…
Phase 1 Randomized, Placebo-Controlled, Dose-Escalating Study to Evaluate OVX836, a Nucleoprotein-Based Influenza Vaccine: Intramuscular Results( )
BACKGROUND: OVX836 is a recombinant protein vaccine targeting the highly conserved influenza nucleoprotein (NP), which could confer broad-spectrum protection against this disease. METHODS: A randomized, placebo-controlled, double-blind, dose-escalating, single- center, first-in-human study was condu...
Autores principales: | Withanage, Kanchanamala, De Coster, Ilse, Cools, Nathalie, Viviani, Simonetta, Tourneur, Jessika, Chevandier, Marion, Lambiel, Manon, Willems, Paul, Le Vert, Alexandre, Nicolas, Florence, Van Damme, Pierre |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9373130/ https://www.ncbi.nlm.nih.gov/pubmed/34653245 http://dx.doi.org/10.1093/infdis/jiab532 |
Ejemplares similares
-
OVX836 Heptameric Nucleoprotein Vaccine Generates Lung Tissue-Resident Memory CD8+ T-Cells for Cross-Protection Against Influenza
por: Del Campo, Judith, et al.
Publicado: (2021) -
Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine
por: Leroux-Roels, Isabel, et al.
Publicado: (2022) -
372. Co-Administration of OVX836, NP-Based Universal Influenza Vaccine Candidate, with Conventional HA-Based Influenza Vaccine: Results of Phase 2a Clinical trial
por: Willems, Paul, et al.
Publicado: (2023) -
OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes
por: Del Campo, Judith, et al.
Publicado: (2019) -
OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model
por: Primard, Charlotte, et al.
Publicado: (2023)